Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

  • End date
    Jun 1, 2024
  • participants needed
  • sponsor
    OHSU Knight Cancer Institute
Updated on 5 July 2022
platelet count
glomerular filtration rate
neutrophil count


This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.



I. To determine the rate of completion of 4 planned high dose methotrexate (HDMTX) doses when glucarpidase is administered after each dose.


I. To assess the length of hospital stay (LOS) associated with methotrexate (MTX) clearance following administration of glucarpidase 24 hours after HDMTX.

II. To assess the LOS associated with all causes following administration of glucarpidase 24 hours after HDMTX.

III. To assess the impact of glucarpidase administration on HDMTX efficacy. IV. To assess the safety and tolerability of 4 doses of HDMTX administered with glucarpidase in an adult osteosarcoma population.

V. To assess the efficacy of glucarpidase flat dose of 1,000 units.


Patients receive standard of care HDMTX intravenously (IV) over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 and 48 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 32 weeks.

Condition Osteosarcoma
Treatment quality-of-life assessment, Glucarpidase, Glucarpidase
Clinical Study IdentifierNCT03960177
SponsorOHSU Knight Cancer Institute
Last Modified on5 July 2022


Yes No Not Sure

Inclusion Criteria

All races and ethnic groups will be eligible
A minimum of 6 individuals aged >= 40 years will be enrolled. These participants are considered high-risk
Eastern Cooperative Oncology Group (ECOG) performance score 0-2
Participants must have pathologically confirmed diagnosis of osteosarcoma. Participants must be newly diagnosed and previously untreated, although initiation of doxorubicin/cisplatin prior to enrollment is permitted
Participants must have a recommended treatment plan for their osteosarcoma that includes planned MTX treatment at 8-12 g/m^2
Absolute neutrophil count (ANC) >= 1,000/mm^3 (or >= 1.0 x 10^9/L)
Platelet count 75,000/mm^3 (or >= 75 x 10^9/L)
Hemoglobin >= 8 g/dL
Serum creatinine =< 1.5 x the upper limit of normal (ULN), or glomerular filtration rate (GFR) >= 60 ml/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) formula
Total serum bilirubin =< 2 x ULN
Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 2.5 x ULN
Participants must be willing to use appropriate contraception for the duration of study treatment and four months after completing HDMTX therapy
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Malignant disease, other than those being treated in this study. Exceptions to this exclusion include the following
Malignancies that were treated curatively and have not recurred within 2 years after completion of treatment
Completely resected basal cell and squamous cell skin cancers
Any malignancy considered to be indolent and that has never required therapy
Completely resected carcinoma in situ of any type
Participants with rapidly progressive disease or organ dysfunction that would prevent
Previous MTX treatment at doses >= 3 g/m^2
them from receiving planned HDMTX treatment regimen
Previous treatment with glucarpidase
Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis. Patients who have completed curative therapy for HCV are eligible. Patients with known history of human immunodeficiency virus (HIV) infection are eligible
Participants with a history of hypersensitivity reactions to study agent or its excipients
Participants with a history of hypersensitivity to Escherichia (E.)coli-derived proteins
Participants with large pleural or ascitic fluid collection
Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
Uncontrolled intercurrent illness, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
Unable or unwilling to discontinue use of agents that interact significantly with methotrexate metabolism or excretion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note